NORTH BRUNSWICK, N.J., Nov. 18, 2016 /PRNewswire/ -- New Jersey Technology Council (NJTC) has honored Chromocell Corporation along with the region's top tech companies and their leaders for their business accomplishments in technological collaboration, partnership and innovation at this year's 20th Anniversary Awards Gala Celebration. The Award was presented on November 17, 2016 at the Palace at Somerset Park, NJ at a celebration of innovation and technology.
Each year the NJTC distinguished panel of judges selects an elite group of companies and individuals to receive this prestigious award.
"Chromocell is honored to be recognized for applying our unique platform technology to transforming the field of analgesics together with other outstanding companies," said Christian Kopfli, Chief Executive Officer of Chromocell. "We are working hard to further develop our lead drug candidate CC8464 in the fast-growing field of pain management to provide a much-needed solution for people suffering from pain conditions."
About the New Jersey Technology Council The New Jersey Technology Council (NJTC) provides business support, networking opportunities, information, advocacy, and recognition of technology companies and their leaders. Founded in 1996, NJTC's member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States. The NJTC offers its member companies access to networking, financing resources, expertise and more. A private, not-for-profit membership organization, the NJTC fosters and grows a vibrant entrepreneurial spirit and nurtures a community where great ideas take flight. For more information visit: http://www.njtc.org
About Chromocell Corporation Chromocell is a life sciences company which improves consumer products and patient lives through breakthrough science and technologies. Chromocell is focused on the discovery and development of therapeutics and flavors through the use of pioneering Chromovert® technology. Chromovert® technology enables Chromocell to use rare cells ideally suited for effective high-throughput screening. Chromocell's therapeutics pipeline is currently focused on analgesics and rare diseases, where Chromovert® technology has proven highly effective in the rapid identification of potential new drug candidates, as well as discovery and development of novel flavor ingredients and natural taste enhancers.